Pharmafile Logo

crowdsourcing

- PMLiVE

Merz pulls out of race for Obagi Medical

Leaves Valeant open to complete takeover

- PMLiVE

Battle lines drawn as Valeant ups Obagi bid

Hits back against Merz offer

- PMLiVE

Merz offers $385m to trump Valeant’s bid for Obagi

Could spark bidding war for dermatology specialist

- PMLiVE

IQWiG knocks back Almirall’s Eklira

Decides added benefit of COPD drug is not proven

Forest Labs launches COPD drug Tudorza in US

Enters a market dominated by Boehringer and Pfizer's Spiriva and GSK's Advair

Almirall appoints first woman to the board

Karin Louise Dorrepaal will serve as an independent board member

- PMLiVE

UCB’s chair Gerhard Mayr joins Almirall board

He becomes an independent director of the Spanish pharma company

Almirall’s IBS drug Constella backed by CHMP

On track to become the first drug specifically approved for the condition

- PMLiVE

Astellas’ Jo Underhill promoted to UK sales and marketing director role

She will head the company’s UK urology and dermatology efforts

Valeant offers $2.6bn to buy dermatology firm Medicis

Possible further addition to long list of Canadian pharma firm’s acquisitions

- PMLiVE

Almirall strikes UK commercial partnership with Quintiles

Agreement will focus on the promotion of Almirall's respiratory portfolio in the UK

- PMLiVE

Interview: Jorge Gallardo, Almirall

The executive chairman of Spanish pharmaceutical company Almirall explains to PME editor Linda Banks how bold investment in R&D and international expansion are key to the company's growth

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links